BIOFEEDBACK IN TREATMENT OF COGNITIVE AND PSYCHO-EMOTIONAL DISORDERS IN PATIENTS WITH EARLY STAGES OF PARKINSON’S DISEASE

Biriuk V. V.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Treatment of non-motor symptoms in patients with early stages of Parkinson’s disease (PD) is the important component of the complex therapy. The clinical effectiveness of biofeedback trainings in treatment of cognitive and psycho-emotional disorders in the early stages of PD was studied in this research. Object and research methods. A total of 38 patients under I-II PD stages were included in this study (age range, 49-75 years). There were 28 PD patients in the biofeedback group and 10 PD patients in the comparison group. Mean age of all patients was 65,2±1,07 years (65,0±1,3 years in the biofeedback group and 65,8±1,88 in the comparison group). Cognitive functions were assessed using the Montreal Cognitive Assessment (MoCA) scale. All the patients were examined with the Beck Depression Inventory (BDI-II), Starkstein Apathy Scale, Zung Anxiety Rating Scale, Vein Night Sleep Scale, Boston Stress Test on the 1-st day of observation, in the end of the biofeedback course in the basic group and in 10±2 days in the comparison group, and in 30±2 days of observation. Results. There was a significant improvement in cognitive and psycho-emotional status in biofeedback group on the last day of course and in 30±2 days further under conditions of independent daily trainings (р<0,05). A significant difference between the final (at the end of dynamical observation) level of cognitive and certain psycho-emotional disorders (in particular, anxiety, reduced stress resistance, sleep disturbances) of the biofeedback group and comparison group was revealed (р<0,05). However, in contrast to the patients of the biofeedback group, who underwent the course of biofeedback training, statistically significant improvement in the psycho-emotional state of patients in the comparison group during the observation period was not detected. Conclusions. Biofeedback trainings can be considered as an expedient component in the complex treatment of cognitive and psycho-emotional disorders in the early PD stages. Prospects for further researches are to study the treatment of cognitive and psycho-emotional disorders in patients with I-II PD stages through the integrated use of biofeedback and neuroprotective therapies with the antiparkinsonian agents.

Parkinson’s disease, biofeedback, cognitive impairment, psycho-emotional disorders, early stages.

1. Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar J, et al. Global, regional, and national burden of Parkinson’s disease, 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):939-53.
2. Holden S, Finseth T, Sillau S, Berman B. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson’s Progression Markers Initiative Cohort. Movement Disorders Clinical Practice. 2017;5(1):47-53.
3. Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience. 2017;18(7):435-50.
4. Seppi K, Ray Chaudhuri K, Coelho M, Fox S, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease – an evidence – based medicine review. Movement Disorders. 2019;34(2):180-98.
5. McAusland L, Addington J. Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis. Early Intervention in Psychiatry. 2016;12(4):694-701.
6. Goessl V, Curtiss J, Hofmann S. The effect of heart rate variability biofeedback training on stress and anxiety: a meta-analysis. Psychological Medicine. 2017;47(15):2578-86.
7. Demchenko AV. Bioadaptyvne upravlinnia v kompleksnomu likuvanni psykhoemotsiinykh rozladiv u khvorykh na khronichnu ishemiiu mozku. Ukrainskyi Nevrolohichnyi Zhurnal. 2016;1:55-61. [in Ukrainian].
8. Banerjee S, Argáez C. Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017. p. 1-26. Available from: https://www.ncbi.nlm.nih. gov/books/NBK531603/
9. Duarte-Moreira R, Castro K, Luz-Santos C, Martins J, Sá K, Baptista A. Electromyographic Biofeedback in Motor Function Recovery After Peripheral Nerve Injury: An Integrative Review of the Literature. Applied Psychophysiology and Biofeedback. 2018;43(4):247-57.
10. Kondo K, Noonan K, Freeman M, Ayers C, Morasco B, Kansagara D. Efficacy of Biofeedback for Medical Conditions: an Evidence Map. Journal of General Internal Medicine. 2019;34(12):2883-93.
11. Steer R, Ball R, Ranieri W, Beck A. Further Evidence for the Construct Validity of the Beck Depression Inventory-II with Psychiatric Outpatients. Psychological Reports. 1997;80(2):443-6.
12. Sielski R, Rief W, Glombiewski J. Efficacy of Biofeedback in Chronic back Pain: a Meta-Analysis. International Journal of Behavioral Medicine. 2016;24(1):25-41.
13. Simón M, Bueno A, Otero P, Vázquez F, Blanco V. A Randomized Controlled Trial on the Effects of Electromyographic Biofeedback on Quality of Life and Bowel Symptoms in Elderly Women With Dyssynergic Defecation. International Journal of Environmental Research and Public Health. 2019;16(18):3247.
14. Kropp P, Meyer B, Meyer W, Dresler T. An update on behavioral treatments in migraine – current knowledge and future options. Expert Review of Neurotherapeutics. 2017;17(11):1059-68.
15. Grebysheva TS, Brazovskaia NG, Zhukova IA, Nikitina MA, Izhboldina OP, i dr. Primenenie bioupravleniia v reabilitatsii patsientov s bolezniu Parkinsona. Biulleten sibirskoi meditsiny. 2014;13(4):38-42. [in Russiаn].
16. Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol J, Taba P, et al. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice. 2017;4(4):536-44.
17. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017 Dec;3(1):17013.
18. Reynolds GO, Hanna KK, Neargarder S, Cronin-Golomb A. The relation of anxiety and cognition in Parkinson’s disease. Neuropsychology. 2017 Sep;31(6):596-604.
19. D’Iorio A, Maggi G, Vitale C, Trojano L, Santangelo G. «Pure apathy» and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study. Neuroscience & Biobehavioral Reviews. 2018 Nov;94:1-10.
20. Santangelo G, D’Iorio A, Maggi G, Cuoco S, Pellecchia MT, Amboni M, et al. Cognitive correlates of «pure apathy» in Parkinson’s disease. Parkinsonism & Related Disorders. 2018 Aug;53:101-4.
21. Trout J, Christiansen T, Bulkley MB, Tanner JJ, Sozda CN, Bowers D, et al. Cognitive Impairments and Self-Reported Sleep in Early-Stage Parkinson’s Disease with Versus without Probable REM Sleep Behavior Disorder. Brain Sciences. 2019 Dec 21;10(1):9.
22. Malak ALSB, Vasconcellos LF, Pereira JS, Greca DV, Cruz M, Alves HVD, et al. Symptoms of depression in patients with mild cognitive impairment in Parkinson’s disease. Dement neuropsychol. 2017 Jun;11(2):145-53.
23. Lee Y, Oh JS, Chung SJ, Lee JJ, Chung SJ, Moon H, et al. The presence of depression in de novo Parkinson’s disease reflects poor motor compensation. PLoS ONE. 2018 Sep 19;13(9):e0203303.
24. Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. CIA. 2015;10:1421-9.
25. Simmons AD. Integrative Medicine (Fourth Edition). Elsevier; 2018. Chapter 15, Parkinson’s Disease. p. 143-51.e3.

«Bulletin of problems biology and medicine» Issue 3 (157), 2020 year, 89-93 pages, index UDK 616.858:[159.942+159.95]]-085.851.8

10.29254/2077-4214-2020-3-157-89-93